Tech Company Financing Transactions
Neurocentrx Pharma Funding Round
On 9/23/2025, Neurocentrx Pharma raised $5 million in Seed funding from private investors.
Transaction Overview
Company Name
Announced On
9/23/2025
Transaction Type
Venture Equity
Amount
$5,000,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to accelerate its clinical development programs.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Level 5, 9 Haymarket Square
Edinburgh, Scotland, EH3 8RY
UK
Edinburgh, Scotland, EH3 8RY
UK
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Neurocentrx is a clinical-stage biopharmaceutical company developing the world's first abuse-deterrent, immediate-release oral ketamine therapy designed for both in-clinic and at-home care settings. Headquartered in Edinburgh, Scotland, with global research collaborations and operations in Australia and the United States, our mission is to transform how care is delivered for people suffering from treatment-resistant mood disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Carmel Reilly
Browse more venture capital transactions:
Prev: 9/23/2025: Fnality venture capital transaction
Next: 9/23/2025: Judi Health venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs